Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 17/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25600339 | 1.00 | OPRL1 (0.37) | OPRL1OPRM1OPRK1HRH3OPRD1 | |
| SCHEMBL24838460 | 0.90 | HRH3 (0.40) | OPRL1OPRM1OPRK1HRH3OPRD1 | |
| SCHEMBL25600501 | 0.90 | HRH3 (0.40) | OPRL1OPRM1OPRK1HRH3OPRD1 | |
| SCHEMBL24838472 | 0.89 | OPRL1 (0.38) | OPRL1OPRM1OPRK1HRH3OPRD1 | |
| SCHEMBL24838158 | 0.89 | OPRL1 (0.38) | OPRL1OPRM1OPRK1HRH3OPRD1 | |
| SCHEMBL25604717 | 0.88 | KDM4E (0.42) | HRH3KDM4EPOLBCHRM1 | |
| SCHEMBL25600401 | 0.84 | HRH3 (0.48) | HRH3 | |
| SCHEMBL25600400 | 0.84 | HRH3 (0.48) | HRH3 | |
| SCHEMBL25630935 | 0.83 | OPRL1 (0.44) | OPRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL25630931 | 0.83 | OPRL1 (0.44) | OPRL1OPRM1OPRK1OPRD1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | OPRL1 4834/4885OPRM1 4706/4885OPRK1 4654/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | OPRL1 4834/4885OPRM1 4706/4885OPRK1 4654/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | OPRL1 4834/4885OPRM1 4706/4885OPRK1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.